Group 1 - Voyager Therapeutics, Inc. is a biotechnology company focused on using genetics to treat neurological diseases, with a pipeline that includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, and ALS [2] - The company will participate in several upcoming investor conferences, including the Citi and Baird fireside chats, where it plans to present preclinical data on its non-viral delivery platform [1][4] - Voyager's TRACER™ AAV capsid discovery platform is utilized to create novel capsids for high brain penetration of genetic medicines [2] Group 2 - The company has partnerships with major pharmaceutical firms such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, and Neurocrine Biosciences, Inc. [2] - Upcoming conference details include the Citi's 2025 Biopharma Back to School Conference on September 2, 2025, and the Wells Fargo Healthcare Conference on September 3, 2025 [4] - The company aims to highlight its innovative approaches to neurotherapeutics during these conferences, particularly its methods for crossing the blood-brain barrier [4]

Company Overview - Voyager Therapeutics, Inc. is a biotechnology company focused on using genetics to treat neurological diseases [3] - The company's pipeline includes programs targeting Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other central nervous system diseases [3] - Voyager utilizes its TRACER™ AAV capsid discovery platform to create novel capsids for enhanced brain penetration of genetic medicines [3] Recent Events - Alfred W. Sandrock, Jr., M.D., Ph.D., CEO of Voyager, will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference [1] - An on-demand webcast of the fireside chat will be available on Voyager's website starting at 7:00 a.m. ET on June 17, 2025, and will be archived for at least 30 days [2]